ORGO — Organogenesis Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $382.69m
- $348.05m
- $433.14m
- 81
- 46
- 62
- 67
Annual cashflow statement for Organogenesis Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -40.5 | 17.2 | 94.9 | 15.5 | 4.95 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 7.05 | 7.69 | 26 | 30.7 | 26.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -9.67 | -27.8 | -37.7 | -34.1 | -18.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -33.5 | 5.47 | 62 | 24.9 | 30.9 |
| Capital Expenditures | -6.23 | -17.7 | -31.2 | -33.9 | -24.4 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | -5.82 | 0 | — | — |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -6.23 | -23.5 | -31.2 | -33.9 | -24.4 |
| Financing Cash Flow Items | 46.4 | 55.6 | -1.22 | -1.26 | -0.332 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 78.7 | 42.5 | -1.04 | -2.2 | -5.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 39 | 24.4 | 29.7 | -11.2 | 1.05 |